A Phase 3 interventional study of Cisplatin and External Beam Radiation Therapy in Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma and Cervical Squamous Cell Carcinoma, Not Otherwise Specified, sponsored by GOG Foundation. Completed at 719 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-23.
Sponsored by GOG Foundation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies testing cisplatin in Uterine Cervical Neoplasms — 10 open to participants now, 11 under way, 3 of them phase 3. Cisplatin · Uterine Cervical Neoplasms.
Among the 80 studies testing cisplatin in Uterine Cervical Neoplasms, this one is the 11th largest by enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2010, is one of 20 in phase 3, and was the 47th registered.
2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →10 of the 80 studies testing cisplatin in Uterine Cervical Neoplasms are open now, in 6 countries. Recruiting first, the newest first:
Denise Fabian · Sites in United States
Ages 18–120 · Women only
Hospital do Coracao · Sites in Brazil
Ages 18–70 · Women only
Tata Memorial Centre · Sites in India
Ages 18–80 · Women only
Chuangzhen Chen · Sites in China
Ages 18–70 · Women only
Chongqing University Cancer Hospital · Sites in China
Ages 18–75 · Women only
By country, each count listing its studies:
Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →
Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 34 · Phase 3 21 · Phase 4 1
First in 1996; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 340 is above the median of 100 across 1,740 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 50 across the 73 interventional studies. Of the 48 that completed or were terminated, 15 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 80 has an industry lead sponsor. The 10 most frequent:
GOG Foundation is the lead sponsor of 18 studies on the registry; 4 are open to participants now.
GOG Foundation has 3 studies filed under Uterine Cervical Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies testing cisplatin in Uterine Cervical Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05764044Phase 3Hospital do CoracaoAdjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer | 2026-12-31 |
| NCT04016389University Health Network, TorontoFIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery | 2026-12 |
| NCT04491942National Cancer Institute (NCI)Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 80 studies testing cisplatin in Uterine Cervical Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized phase III trial studies radiation therapy with chemotherapy to see how well they work compared to radiation therapy alone in treating patients with stage I-IIA cervical cancer who previously underwent surgery. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving radiation therapy together with chemotherapy is more effective than radiation therapy alone in treating patients with cervical cancer.
PRIMARY OBJECTIVE:
I. To determine if post-operative adjuvant chemo-radiation therapy (CRT) can significantly improve recurrence-free survival (RFS) when compared to radiation therapy (RT) alone in stage I-IIA cervical cancer patients with intermediate-risk factors after treatment with radical hysterectomy.
SECONDARY OBJECTIVES:
I. To determine whether post-operative adjuvant CRT can improve overall survival (OS) when compared to RT alone in stage I-IIA cervical cancer patients with intermediate risk factors after treatment with radical hysterectomy.
II. To assess differences (across treatment arms) in incidence and severity of therapy attributed adverse events utilizing the active version of Common Terminology Criteria for Adverse Events (CTCAE).
III. To provide assessment of patient risk version (vs) benefit (positive study only).
QUALITY OF LIFE OBJECTIVE:
I. To determine whether post-operative adjuvant CRT improves the health-related quality-of-life (QOL) (compared to RT alone) as measured by Functional Assessment of Cancer Therapy-Cervix (FACT-Cx) Trial Outcome Index (TOI) and produce favorable toxicity profiles (with particular focus on treatment related genitourinary, gastrointestinal, neurological, pain and sexual adverse events).
TRANSLATIONAL RESEARCH OBJECTIVES:
I. To bank archival tumor tissue for research studies, including studies that evaluate the association between biomarkers, RFS, OS, and clinical-surgical-pathologic characteristics in patients randomized to post-operative adjuvant CRT compared to RT alone.
II. To bank deoxyribonucleic acid (DNA) from whole blood for research studies, including studies that evaluate associations between single nucleotide polymorphisms (SNPs), and measures of clinical outcome, including RFS, OS, and adverse events in patients randomized to post-operative adjuvant CRT compared to RT alone.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients undergo pelvic external-beam radiation therapy (EBRT) or intensity-modulated radiation therapy (IMRT) 5 days a week for 5.5 weeks.
ARM II: Patients receive cisplatin IV over 1-2 hours on day 1 and undergo radiotherapy as in Arm I. Treatment with cisplatin repeats every 7 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with the following characteristics (depth of stromal invasion and lymphovascular space involvement to be pathologically confirmed):
Positive capillary-lymphovascular space involvement and one of the following:
Negative capillary-lymphatic space involvement
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergo pelvic EBRT or IMRT once daily, 5 days a week, for 5.5 weeks.
Radiation: External Beam Radiation Therapy · Radiation: Intensity-Modulated Radiation Therapy · Other: Laboratory Biomarker Analysis · Other: Quality-of-Life Assessment · Other: Questionnaire Administration
Patients receive cisplatin IV over 1-2 hours on day 1 and undergo radiotherapy as in Arm I. Treatment with cisplatin repeats every 7 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Drug: Cisplatin · Radiation: External Beam Radiation Therapy · Radiation: Intensity-Modulated Radiation Therapy · Other: Laboratory Biomarker Analysis · Other: Quality-of-Life Assessment · Other: Questionnaire Administration
Given IV
Also known as: Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone''s Chloride, Peyrone''s Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin
Undergo radiotherapy
Also known as: Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam
Undergo radiotherapy
Also known as: IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy
Correlative studies
Ancillary studies
Also known as: Quality of Life Assessment
Ancillary studies
Recurrence-free Survival (RFS) Rate at 3-years
Estimate for probability of RFS at 3 years using Kaplan-Meier method, where RFS is defined as time from protocol registration (and randomization) to the date of first documented recurrence, death, or the date of last contact, whichever occurs first. Patients without recurrence or death were censored at the date of last contact.
Time frame: 3 years from randomization
Overall Survival (OS) Rate at 3-years
Estimate for probability of overall survival at 3 years by Kaplan-Meier method, where overall survival is defined as the time from randomization to time of death due to any cause or the date of last contact, whichever occurs first.
Time frame: 3 years from randomization
Number of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period.
Number of participants with a maximum grade of 3 or higher during treatment period. Adverse events are graded and categorized using CTCAE v4.0.
Time frame: During treatment period and up to 21 days after stopping the study treatment. The median treatment duration was 39 days.
Patient Risk-benefit
The reporting group (2) did not demonstrate improved RFS compared to the reporting group (1) at the pre-specified significance level. Per the protocol, patient risk-benefit will be assessed only for a positive study. This is not assessed due to non-positive study per the protocol.
Time frame: up to 11 years
Quality of Life (QOL) as Measured With the FACT-Cx TOI
The patient-reported QOL is assessed with the Trial Outcome Index of the Functional Assessment of Cancer Therapy-Cervix (FACT-Cx TOI). The FACT-Cx TOI is ranged 0-116 and a larger FACT-Cx TOI score suggests a favorable QoL.
Time frame: 1. Pre-treatment (baseline), 2. 3 weeks following the first day of treatment, 3. 7 weeks following the first day of treatment, 4. 36 weeks following the first day of treatment.
Treatment Compliance
Assessed by the number of cycles and amount of chemoradiotherapy administered, treatment span, incidence and duration of treatment delays, reason for delays, and reason why off study therapy.
Time frame: Up to 11 years
Site(s) of Recurrence
The site(s) of first disease recurrence will be classified as: pelvic-only, extra-pelvic-only or pelvic-and-extra-pelvic and tabulated by treatment group. The test of the hypothesis that the probability of local failure is independent of randomized treatment will be assessed with exact logistic regression adjusted know prognostic factors.
Time frame: Up to 11 years
Local Control
Assessed with Exact Logistic Regression adjusted known prognostic factors.
Time frame: Up to 11 years
GOG-0263 opened to accrual on April 12, 2010, and closed to accrual on April 11, 2022.
| Milestone | Arm I (Radiation) | Arm II (Cisplatin + Radiation) |
|---|---|---|
| Started | 172 | 168 |
| Completed | 158 | 153 |
| Not completed | 14 | 15 |
| Withdrew: Eligible and never treated | 0 | 5 |
| Withdrew: Ineligible and treated | 12 | 8 |
| Withdrew: Ineligible and never treated | 2 | 2 |
Estimate for probability of RFS at 3 years using Kaplan-Meier method, where RFS is defined as time from protocol registration (and randomization) to the date of first documented recurrence, death, or the date of last contact, whichever occurs first. Patients without recurrence or death were censored at the date of last contact.
| percentage of participants | Arm I (Radiation) | Arm II (Cisplatin + Radiation) |
|---|---|---|
| Recurrence-free Survival (RFS) Rate at 3-years | 85.4 (79 to 90) | 88.5 (82 to 93) |
Estimate for probability of overall survival at 3 years by Kaplan-Meier method, where overall survival is defined as the time from randomization to time of death due to any cause or the date of last contact, whichever occurs first.
| percentage of participants | Arm I (Radiation) | Arm II (Cisplatin + Radiation) |
|---|---|---|
| Overall Survival (OS) Rate at 3-years | 90.3 (84 to 94) | 97.2 (93 to 99) |
Number of participants with a maximum grade of 3 or higher during treatment period. Adverse events are graded and categorized using CTCAE v4.0.
| Participants | Arm I (Radiation) | Arm II (Cisplatin + Radiation) |
|---|---|---|
| Anemia | 1 | 6 |
| Other blood/lymphatics | 0 | 4 |
| White blood cell decreased | 3 | 45 |
| Platelet count decreased | 0 | 4 |
| Neutrophil count decreased | 2 | 27 |
| Other investigations | 7 | 8 |
| Gastrointestinal | 10 | 12 |
| General and administration site | 2 | 3 |
| Infections/infestations | 4 | 4 |
| Metabolism/nutrition | 0 | 7 |
| Musculoskeletal/connective tissue | 1 | 0 |
| Nervous system | 2 | 1 |
| Psychiatric | 1 | 1 |
| Renal/urinary | 2 | 2 |
| Reproductive/breast | 2 | 1 |
| Skin/subcutaneous | 0 | 3 |
| Vascular disorders | 0 | 1 |
The reporting group (2) did not demonstrate improved RFS compared to the reporting group (1) at the pre-specified significance level. Per the protocol, patient risk-benefit will be assessed only for a positive study. This is not assessed due to non-positive study per the protocol.
No measurements were reported for this outcome.
The patient-reported QOL is assessed with the Trial Outcome Index of the Functional Assessment of Cancer Therapy-Cervix (FACT-Cx TOI). The FACT-Cx TOI is ranged 0-116 and a larger FACT-Cx TOI score suggests a favorable QoL.
| units on a scale | Arm I (Radiation) | Arm II (Cisplatin + Radiation) |
|---|---|---|
| Baseline | 83.5 ± 15.4 | 80.1 ± 15.4 |
| 3 weeks | 79.0 ± 16.4 | 71.4 ± 15.3 |
| 7 weeks | 80.1 ± 17.0 | 71.8 ± 17.1 |
| 36 weeks | 88.8 ± 15.5 | 88.1 ± 12.3 |
Assessed by the number of cycles and amount of chemoradiotherapy administered, treatment span, incidence and duration of treatment delays, reason for delays, and reason why off study therapy.
Results for this outcome have not been posted.
The site(s) of first disease recurrence will be classified as: pelvic-only, extra-pelvic-only or pelvic-and-extra-pelvic and tabulated by treatment group. The test of the hypothesis that the probability of local failure is independent of randomized treatment will be assessed with exact logistic regression adjusted know prognostic factors.
Results for this outcome have not been posted.
Assessed with Exact Logistic Regression adjusted known prognostic factors.
Results for this outcome have not been posted.
Collected over During treatment period and up to 21 days after stopping the study treatment. The median treatment duration was 39 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm I (Radiation) | 20/158 (12.7%) | 7/170 (4.1%) | 140/170 (82.4%) |
| Arm II (Cisplatin + Radiation) | 12/158 (7.6%) | 9/161 (5.6%) | 158/161 (98.1%) |
| Event | Arm I (Radiation) | Arm II (Cisplatin + Radiation) |
|---|---|---|
| NauseaGastrointestinal disorders | 0/170 | 2/161 |
| White Blood Cell DecreasedInvestigations | 0/170 | 2/161 |
| Blood And Lymphatic System Disorders - OtherBlood and lymphatic system disorders | 0/170 | 1/161 |
| VomitingGastrointestinal disorders | 0/170 | 1/161 |
| HypomagnesemiaMetabolism and nutrition disorders | 0/170 | 1/161 |
| HypokalemiaMetabolism and nutrition disorders | 0/170 | 1/161 |
| SeizureNervous system disorders | 0/170 | 1/161 |
| Urinary Tract ObstructionRenal and urinary disorders | 1/170 | 1/161 |
| Colonic FistulaGastrointestinal disorders | 1/170 | 0/161 |
| Abdominal PainGastrointestinal disorders | 1/170 | 0/161 |
| Event | Arm I (Radiation) | Arm II (Cisplatin + Radiation) |
|---|---|---|
| White Blood Cell DecreasedInvestigations | 73/170 | 121/161 |
| NauseaGastrointestinal disorders | 61/170 | 117/161 |
| AnemiaBlood and lymphatic system disorders | 63/170 | 95/161 |
| Neutrophil Count DecreasedInvestigations | 36/170 | 88/161 |
| DiarrheaGastrointestinal disorders | 76/170 | 78/161 |
| FatigueGeneral disorders | 46/170 | 74/161 |
| Platelet Count DecreasedInvestigations | 19/170 | 73/161 |
| ConstipationGastrointestinal disorders | 26/170 | 63/161 |
| AnorexiaMetabolism and nutrition disorders | 18/170 | 48/161 |
| VomitingGastrointestinal disorders | 14/170 | 37/161 |
Eligible
| Age, Customized(Participants) | Arm I (Radiation) | Arm II (Cisplatin + Radiation) | Total |
|---|---|---|---|
| 20-29 years | 3 | 2 | 5 |
| 30-39 years | 28 | 47 | 75 |
| 40-49 years | 62 | 53 | 115 |
| 50-59 years | 46 | 33 | 79 |
| 60-69 years | 13 | 17 | 30 |
| 70-79 years | 5 | 6 | 11 |
| >= 80 years | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | Arm I (Radiation) | Arm II (Cisplatin + Radiation) | Total |
|---|---|---|---|
| Female | 158 | 158 | 316 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Arm I (Radiation) | Arm II (Cisplatin + Radiation) | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 15 | 27 |
| Not Hispanic or Latino | 142 | 142 | 284 |
| Unknown or Not Reported | 4 | 1 | 5 |
| Race (NIH/OMB)(Participants) | Arm I (Radiation) | Arm II (Cisplatin + Radiation) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 4 |
| Asian | 79 | 87 | 166 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 12 | 5 | 17 |
| White | 62 | 58 | 120 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 6 | 8 |
Showing the first 100 of 719 sites across 3 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2010 to primary completion in Jan 2024, 165 months.
Results were first posted in May 2025, 1 year 3 months after primary completion.
Of 53 non-industry phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 107. This study's 165 months is above that.
Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cisplatin
GOG Foundation